GlassScriptPhysician profile
Kimberly Canaday
NPI 1548280845
$13,099.37
in general payments reported to CMS, 2019-2025
65 companies · $3,021 in 2025
The $3,021 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,934 · 2022: $2,698 · 2023: $2,554 · 2024: $2,893 · 2025: $3,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,451 · Education: $17.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,450.54 |
| Education | $17.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,724.63 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,718.69 | 2021-2025 | Imfinzi, Lynparza, Tagrisso |
| Merck Sharp & Dohme LLC | $571.19 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $475.02 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Pfizer INC. | $450.05 | 2021-2025 | |
| Incyte Corporation | $442.86 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $441.80 | 2021-2023 | Lumakras, Vectibix, Nplate |
| Exelixis INC. | $436.75 | 2021-2025 | Cabometyx |
| Janssen Biotech, INC. | $404.48 | 2021-2025 | Rybrevant, Darzalex, Talvey |
| Celgene Corporation | $359.31 | 2021-2025 | Reblozyl, Pomalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.48 | 2021-2025 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $276.86 | 2021-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $273.72 | 2021-2025 | Jaypirca, Verzenio |
| Eisai INC. | $266.24 | 2021-2025 | |
| Array Biopharma INC | $259.09 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $257.05 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $254.18 | 2022-2025 | Opdivo, Opdualag |
| Genzyme Corporation | $234.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $232.07 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Stemline Therapeutics INC. | $216.58 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $200.58 | 2022-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $195.64 | 2021-2025 | |
| Astellas Pharma US INC | $187.18 | 2021-2025 | Xtandi |
| Beone Medicines USA, INC. | $168.41 | 2025 | Brukinsa, Tevimbra |
| Tersera Therapeutics LLC | $160.38 | 2023-2024 | Xermelo, Zoladex, Quzyttir |
| Sobi, INC | $158.30 | 2022-2025 | |
| Gilead Sciences, INC. | $154.25 | 2021-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $152.68 | 2021-2024 | Soliris, Ultomiris |
| Genentech USA, INC. | $151.43 | 2023-2025 | Tecentriq, Polivy, Venclexta |
| Jazz Pharmaceuticals INC. | $149.13 | 2021-2025 | |
| Beigene USA, INC. | $147.39 | 2022-2025 | Brukinsa, Tevimbra |
| Janssen Scientific Affairs, LLC | $143.79 | 2025 | Rybrevant, Tecvayli, Erleada |
| Daiichi Sankyo INC. | $138.20 | 2021-2025 | Enhertu, Datroway |
| Aveo Pharmaceuticals, INC. | $121.92 | 2021-2025 | Fotivda |
| Kite Pharma, INC. | $120.58 | 2021-2025 | Yescarta |
| Pharmacosmos Therapeutics INC. | $115.80 | 2022-2023 | Monoferric |
| Blueprint Medicines Corporation | $115.31 | 2022-2024 | Ayvakit |
| Puma Biotechnology, INC. | $97.90 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $83.67 | 2021-2024 | Libtayo |
| Coherus Oncology, INC. | $82.47 | 2022-2025 | Loqtorzi |
| Karyopharm Therapeutics INC. | $68.83 | 2021-2023 | Xpovio |
| Dendreon Pharmaceuticals LLC | $62.76 | 2025 | Provenge |
| Pharmaessentia USA Corporation | $46.86 | 2023-2025 | Besremi |
| Kyowa Kirin, INC. | $41.27 | 2025 | |
| Geron Corporation | $41.09 | 2025 | Rytelo |
| Emd Serono, INC. | $36.51 | 2023 | Tepmetko, Bavencio |
| Genmab U.S., INC. | $35.58 | 2023-2024 | Epkinly |
| Sumitomo Pharma America, INC. | $27.76 | 2023 | Orgovyx |
| Iovance Biotherapeutics, INC. | $22.91 | 2024 | Amtagvi |
| Springworks Therapeutics, INC. | $20.96 | 2025 | Ogsiveo |
| Shield Therapeutics INC | $20.40 | 2024 | |
| Tolmar, INC. | $20.24 | 2025 | Eligard |
| Acceleron Pharma, INC. | $19.86 | 2021 | |
| Deciphera Pharmaceuticals INC. | $19.29 | 2023 | Qinlock |
| Servier Pharmaceuticals LLC | $17.97 | 2024 | |
| G1 Therapeutics, INC. | $17.96 | 2023 | Cosela |
| Myovant Sciences INC. | $17.82 | 2022 | |
| Adaptive Biotechnologies Corporation | $17.37 | 2024 | Clonoseq |
| Adc Therapeutics America, INC. | $16.25 | 2023 | |
| Recordati_rare_diseases_inc. | $16.24 | 2025 | Sylvant |
| Rigel Pharmaceuticals, INC. | $15.84 | 2022 | |
| Agios Pharmaceuticals, INC. | $15.72 | 2025 | Pyrukynd |
| Taiho Oncology, INC. | $14.88 | 2021 | |
| Verity Pharmaceuticals INC. | $14.50 | 2023 | Trelstar |
| Fennec Pharmaceuticals, INC. | $14.37 | 2025 | Fyarro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Canaday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.